SERINA THERAPEUTICS INC.
SERNYSE AMERICANTrading Snapshot
- Day Range
- $2.77 – $2.80
- 52-Week Range
- $1.22 – $7.92
- Volume
- $2.67B
- Avg Volume
- $3.55B
- Shares Outstanding
- 15.0M
- Next Earnings
- Sep 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $151,064
- Last Q Revenue
- $35,684
- P/E Ratio
- —
- P/S Ratio
- 276.0x
- EPS (TTM)
- $-1.89
- Dividend Yield
- —
Why Investors Own SER
- ✓High-growth profile — revenue up +5.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SERINA THERAPEUTICS INC.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will hold virtual one-on-one investor meetings on Wednesday, July 29, 2026. Please contact your BTIG representative to reques
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol - - Company expects to provide a further update following completion of the Safety Monitoring Committee review – HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a c
Serina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s Disease
- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 -- Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective immediately. Dr. Simon will also serve on the Board's Audit and Compensation Committees. “We are pleased to welcome Dr. Simon to Serina’s Board of Directors,” said S